| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Arcus Biosciences Inc (NYSE: RCUS)
RCUS Technical Analysis
5
| As on 9th Jun 2023 RCUS STOCK Price closed @ 21.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 28.61 & Strong Sell for SHORT-TERM with Stoploss of 34.90 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RCUSSTOCK Price
| Open | 21.80 | Change | Price | % |
| High | 21.98 | 1 Day | -0.54 | -2.50 |
| Low | 20.89 | 1 Week | 0.84 | 4.15 |
| Close | 21.10 | 1 Month | 3.11 | 17.29 |
| Volume | 1334814 | 1 Year | -20.53 | -49.32 |
| 52 Week High 44.59 | 52 Week Low 15.96 | ||||
NYSE USA Most Active Stocks
| DDR | 15.44 | -4.46% |
| NIO | 7.73 | -0.77% |
| TWTR | 53.70 | 0.66% |
| CVNA | 19.07 | -21.30% |
| BACA-U | 302.00 | 0.67% |
| PLTR | 15.02 | -1.12% |
| F | 13.74 | 1.18% |
| CS | 0.89 | 1.14% |
| RPAI | 13.15 | -3.17% |
| AUY | 5.85 | -0.68% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| RCUS Daily Charts |
RCUS Intraday Charts |
Whats New @ Bazaartrend |
RCUS Free Analysis |
|
|
RCUS Important Levels Intraday
| RESISTANCE | 23.20 |
| RESISTANCE | 22.53 |
| RESISTANCE | 22.11 |
| RESISTANCE | 21.69 |
| SUPPORT | 20.51 |
| SUPPORT | 20.09 |
| SUPPORT | 19.67 |
| SUPPORT | 19.00 |
RCUS Forecast May 2024
| 4th UP Forecast | 44.74 |
| 3rd UP Forecast | 37.16 |
| 2nd UP Forecast | 32.47 |
| 1st UP Forecast | 27.79 |
| 1st DOWN Forecast | 14.41 |
| 2nd DOWN Forecast | 9.73 |
| 3rd DOWN Forecast | 5.04 |
| 4th DOWN Forecast | -2.54 |
RCUS Weekly Forecast
| 4th UP Forecast | 32.35 |
| 3rd UP Forecast | 28.74 |
| 2nd UP Forecast | 26.51 |
| 1st UP Forecast | 24.28 |
| 1st DOWN Forecast | 17.92 |
| 2nd DOWN Forecast | 15.69 |
| 3rd DOWN Forecast | 13.46 |
| 4th DOWN Forecast | 9.85 |
RCUS Forecast2024
| 4th UP Forecast | 79.3 |
| 3rd UP Forecast | 60.63 |
| 2nd UP Forecast | 49.1 |
| 1st UP Forecast | 37.56 |
| 1st DOWN Forecast | 4.64 |
| 2nd DOWN Forecast | -6.9 |
| 3rd DOWN Forecast | -18.43 |
| 4th DOWN Forecast | -37.1 |
Arcus Biosciences Inc ( NYSE USA Symbol : RCUS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RCUS Business Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California. Address: 3928 Point Eden Way, Hayward, CA, United States, 94545
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service